Latest Regulatory Clearance News

Recce Pharmaceuticals bolsters its clinical and commercial pipeline with a $5.3 million AUD R&D tax rebate, a second U.S. Army research agreement for its RECCE 327 Gel, and a key patent granted in Brazil, while progressing Phase 3 trials in Indonesia.

Boab Metals has secured a A$236 million syndicated loan and final regulatory approvals, accelerating construction at its Sorby Hills Silver-Lead-Zinc Project with production on track for H2 2027.

4DMedical has made significant strides in commercial adoption of its CT:VQ™ lung imaging technology, securing top US hospital contracts, regulatory approvals in Europe and the UK, and a major pharmaceutical partnership, all backed by strong capital raises and inclusion in the S&P/ASX 200.

Blackstone Minerals has cleared a key regulatory hurdle at its Mankayan Copper-Gold Project, lifting a Cease and Desist Order and initiating a Pre-Feasibility Study. The company also strengthened its board with mining veteran Mark Williams and reported a solid cash position of $14.6 million.

Pacific Equity Partners has tabled a non-binding offer to acquire oOh!media for A$1.40 per share via a scheme of arrangement, triggering a strategic review by the board amid regulatory hurdles and due diligence conditions.

Diamond Infraco 1 Pty Ltd, backed by IFM Global Infrastructure Fund, has tabled an all-cash takeover offer for the remaining Atlas Arteria securities at A$4.75, rising to A$5.10 if a 45% stake is secured. The bid comes amid concerns over Atlas Arteria’s recent strategic pivot and operational underperformance.

Diatreme Resources reported a $745,000 net loss for FY 2025 but strengthened its financial footing through asset sales and an IPO stake. The company’s Northern Silica Project and Cyclone Zircon Project showed significant technical progress, while a major Cape Flattery asset sale aims to streamline operations and unlock funding.

Qube Holdings Limited is set for a $9.3 billion cash takeover by a Macquarie-led consortium, with court approval granted to convene shareholder meetings in June. The scheme offers shareholders a 28% premium and is backed by an independent expert's fair and reasonable opinion.

Ampol has increased its divestment offer to the ACCC by four additional sites, raising the total to 41 as it pushes to satisfy competition concerns in its EG Australia acquisition. The move aims to secure regulatory clearance ahead of a mid-2026 transaction close.

Multistack International is progressing with the sale of its core assets to Willing Y Limited, maintaining operations cautiously while cash reserves decline amid ongoing operating losses.

Ramsay Health Care has announced a fully franked distribution of AUD 3.3608 per security on its perpetual preference shares, subject to board approval by late August. The payment reflects a total annualised rate of 6.7%, linked to the 180-day BBSW plus a margin.

4DMedical lands a contract with pharma giant GSK, gains UKCA certification for its CT:VQ™ lung imaging technology, and joins the S&P/ASX 200, marking a significant step in its global expansion.